Nivolumab plus ipilimumab is indicated in the USA and other countries for the first-line treatment of adults with metastatic NSCLC with PD-L1 ≥ 1% and no EGFR or ALK genomic tumor aberrations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.